IL156261A0 - Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same - Google Patents
Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL156261A0 IL156261A0 IL15626101A IL15626101A IL156261A0 IL 156261 A0 IL156261 A0 IL 156261A0 IL 15626101 A IL15626101 A IL 15626101A IL 15626101 A IL15626101 A IL 15626101A IL 156261 A0 IL156261 A0 IL 156261A0
- Authority
- IL
- Israel
- Prior art keywords
- disorders
- novel compounds
- pyridoquinoline
- pyrroloquinoline
- derivatives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OZKOMUDCMCEDTM-UHFFFAOYSA-N 1,7-phenanthroline Chemical class C1=CC=C2C3=NC=CC=C3C=CC2=N1 OZKOMUDCMCEDTM-UHFFFAOYSA-N 0.000 title 1
- ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 7h-pyrrolo[2,3-h]quinoline Chemical compound C1=CN=C2C(C=CN3)=C3C=CC2=C1 ZIUYHTQZEPDUCZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003420 antiserotonin agent Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000952 serotonin receptor agonist Substances 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25674500P | 2000-12-20 | 2000-12-20 | |
| PCT/US2001/049380 WO2002059124A2 (fr) | 2000-12-20 | 2001-12-19 | Pyrroloquinoleines et pyridoquinoleines substituees comme agonistes et antagonistes de la serotonine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL156261A0 true IL156261A0 (en) | 2004-01-04 |
Family
ID=22973430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15626101A IL156261A0 (en) | 2000-12-20 | 2001-12-19 | Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6777406B2 (fr) |
| EP (1) | EP1399445B9 (fr) |
| JP (1) | JP4386639B2 (fr) |
| KR (1) | KR20030070590A (fr) |
| AT (1) | ATE438646T1 (fr) |
| AU (1) | AU2002246726B2 (fr) |
| BG (1) | BG107863A (fr) |
| BR (1) | BR0116348A (fr) |
| CA (1) | CA2432181C (fr) |
| CZ (1) | CZ20031707A3 (fr) |
| DE (1) | DE60139511D1 (fr) |
| EE (1) | EE200300303A (fr) |
| ES (1) | ES2329553T4 (fr) |
| HU (1) | HUP0303530A3 (fr) |
| IL (1) | IL156261A0 (fr) |
| IS (1) | IS6851A (fr) |
| MX (1) | MXPA03005355A (fr) |
| NO (1) | NO20032798L (fr) |
| PL (1) | PL366627A1 (fr) |
| RU (1) | RU2003121306A (fr) |
| SK (1) | SK7032003A3 (fr) |
| WO (1) | WO2002059124A2 (fr) |
| ZA (1) | ZA200304304B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR031202A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados |
| AR031199A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados |
| AR031200A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| EP2400300A1 (fr) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress |
| US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
| US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
| GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
| CN101410118A (zh) * | 2006-03-24 | 2009-04-15 | 惠氏公司 | 疼痛的治疗 |
| CA2644662A1 (fr) * | 2006-03-24 | 2007-10-04 | Wyeth | Nouvelles combinaisons therapeutiques pour le traitement de la depression |
| EP2018863B9 (fr) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné et utilisation |
| CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
| EP2216023A4 (fr) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | Dérivé de pyridine condensé et son utilisation |
| WO2011044506A2 (fr) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Composés sulfonés et leurs procédés de fabrication et d'utilisation |
| WO2011071136A1 (fr) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | Agent thérapeutique pour la fibromyalgie |
| AU2011281037B2 (en) * | 2010-07-22 | 2014-11-27 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| CA2825408A1 (fr) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Composes de tetrazole et procedes de preparation et d'utilisation de ceux-ci |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| CA2835195A1 (fr) | 2011-05-06 | 2012-11-15 | Zafgen, Inc. | Composes de sulfonamide tricycliques et leurs procedes de fabrication et d'utilisation |
| WO2012154676A1 (fr) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Composés tricycliques partiellement saturés et leurs procédés de fabrication et d'utilisation |
| KR20140112566A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| MX2014008706A (es) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| EP2925737B1 (fr) | 2012-11-05 | 2017-06-14 | Zafgen, Inc. | Composés tricycliques à utiliser dans le traitement et/ou la lutte contre l'obésité |
| CA2890343A1 (fr) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Composes tricycliques utiles pour le traitement de troubles hepatiques |
| AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2981266B1 (fr) * | 2013-03-04 | 2018-01-03 | Daya CNS LLC | Dérivés de pyridoindolobenz[b,d]azépines pentacycliques et leurs utilisations |
| WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| CN109897039B (zh) * | 2019-03-13 | 2021-03-30 | 中国科学院化学研究所 | 一种制备吡咯并[3,2,1-ij]喹啉酮化合物的方法 |
| KR20230170053A (ko) * | 2021-04-13 | 2023-12-18 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 테트라사이클릭 화합물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4013652A (en) | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| HUT61548A (en) | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
-
2001
- 2001-12-19 DE DE60139511T patent/DE60139511D1/de not_active Expired - Lifetime
- 2001-12-19 EP EP01994318A patent/EP1399445B9/fr not_active Expired - Lifetime
- 2001-12-19 AT AT01994318T patent/ATE438646T1/de not_active IP Right Cessation
- 2001-12-19 AU AU2002246726A patent/AU2002246726B2/en not_active Ceased
- 2001-12-19 KR KR10-2003-7008267A patent/KR20030070590A/ko not_active Application Discontinuation
- 2001-12-19 IL IL15626101A patent/IL156261A0/xx unknown
- 2001-12-19 CA CA002432181A patent/CA2432181C/fr not_active Expired - Fee Related
- 2001-12-19 RU RU2003121306/04A patent/RU2003121306A/ru not_active Application Discontinuation
- 2001-12-19 JP JP2002559426A patent/JP4386639B2/ja not_active Expired - Fee Related
- 2001-12-19 BR BR0116348-5A patent/BR0116348A/pt not_active Application Discontinuation
- 2001-12-19 SK SK703-2003A patent/SK7032003A3/sk unknown
- 2001-12-19 HU HU0303530A patent/HUP0303530A3/hu unknown
- 2001-12-19 WO PCT/US2001/049380 patent/WO2002059124A2/fr active IP Right Grant
- 2001-12-19 MX MXPA03005355A patent/MXPA03005355A/es unknown
- 2001-12-19 PL PL01366627A patent/PL366627A1/xx unknown
- 2001-12-19 US US10/026,993 patent/US6777406B2/en not_active Expired - Lifetime
- 2001-12-19 ES ES01994318T patent/ES2329553T4/es not_active Expired - Lifetime
- 2001-12-19 CZ CZ20031707A patent/CZ20031707A3/cs unknown
- 2001-12-19 EE EEP200300303A patent/EE200300303A/xx unknown
-
2003
- 2003-05-30 BG BG107863A patent/BG107863A/xx unknown
- 2003-06-02 ZA ZA200304304A patent/ZA200304304B/en unknown
- 2003-06-18 IS IS6851A patent/IS6851A/is unknown
- 2003-06-19 NO NO20032798A patent/NO20032798L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003121306A (ru) | 2005-03-10 |
| AU2002246726B2 (en) | 2007-03-01 |
| ATE438646T1 (de) | 2009-08-15 |
| MXPA03005355A (es) | 2004-05-27 |
| CA2432181C (fr) | 2009-11-17 |
| BR0116348A (pt) | 2004-11-23 |
| EE200300303A (et) | 2003-12-15 |
| CZ20031707A3 (cs) | 2003-11-12 |
| NO20032798L (no) | 2003-08-19 |
| ES2329553T4 (es) | 2010-12-07 |
| ZA200304304B (en) | 2004-09-02 |
| HUP0303530A3 (en) | 2012-10-29 |
| EP1399445B9 (fr) | 2010-07-21 |
| BG107863A (en) | 2004-06-30 |
| EP1399445A2 (fr) | 2004-03-24 |
| ES2329553T3 (es) | 2009-11-27 |
| JP2004528290A (ja) | 2004-09-16 |
| WO2002059124A2 (fr) | 2002-08-01 |
| KR20030070590A (ko) | 2003-08-30 |
| NO20032798D0 (no) | 2003-06-19 |
| DE60139511D1 (de) | 2009-09-17 |
| PL366627A1 (en) | 2005-02-07 |
| US6777406B2 (en) | 2004-08-17 |
| US20040092502A1 (en) | 2004-05-13 |
| EP1399445B1 (fr) | 2009-08-05 |
| SK7032003A3 (en) | 2004-04-06 |
| HUP0303530A2 (hu) | 2004-01-28 |
| IS6851A (is) | 2003-06-18 |
| CA2432181A1 (fr) | 2002-08-01 |
| WO2002059124A3 (fr) | 2004-01-08 |
| JP4386639B2 (ja) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156261A0 (en) | Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same | |
| WO2002059129A3 (fr) | Pyridoindoles substitues en tant qu'agonistes et antagonistes de serotonine | |
| WO2000077010A3 (fr) | Gamma-carbolines fusionnees a heterocycles substitues | |
| AU2003303210A8 (en) | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | |
| HK1098460A1 (en) | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders | |
| IL156201A0 (en) | Pyrazinoquioxaline derivatives and pharmaceutical compositions containing the same | |
| HUP0303316A2 (hu) | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények | |
| GB0311349D0 (en) | Therapeutic agents, compositions, preparations and uses |